GlassScriptPhysician profile
Mark Finley
NPI 1992077333
$10,479.49
in general payments reported to CMS, 2019-2025
32 companies · $2,488 in 2025
The $2,488 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,556 · 2022: $2,093 · 2023: $2,149 · 2024: $2,193 · 2025: $2,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,281 · Education: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,281.33 |
| Education | $548.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,556.82 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,401.85 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,039.72 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $994.81 | 2022-2025 | |
| Janssen Biotech, INC. | $984.53 | 2021-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $863.53 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $848.12 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Leo Pharma INC. | $415.64 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $377.08 | 2022-2025 | Sotyktu |
| Ucb, INC. | $305.30 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $271.12 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $211.17 | 2023-2024 | Vtama |
| Pfizer INC. | $206.19 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $163.50 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $152.38 | 2021-2025 | Nemluvio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Incyte Corporation | $93.69 | 2023-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $93.34 | 2022-2024 | |
| Vyne Pharmaceuticals INC. | $67.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.84 | 2023-2024 | Spevigo, Cyltezo |
| Mallinckrodt Hospital Products INC. | $45.34 | 2024 | Acthar |
| Almirall LLC | $44.50 | 2023-2024 | Seysara |
| Merck Sharp & Dohme LLC | $24.26 | 2022 | |
| Kerecis Limited | $22.81 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Strata Skin Sciences, INC. | $21.36 | 2025 | Xtrac |
| Genentech USA, INC. | $21.34 | 2022 | |
| Organon LLC | $20.85 | 2025 | Vtama |
| Abbott Laboratories | $20.72 | 2022 | |
| Mimedx Group, INC. | $15.98 | 2024 | |
| Verrica Pharmaceuticals INC. | $14.14 | 2023 | Ycanth |
| Kowa Pharmaceuticals America, INC. | $13.49 | 2022 | |
| Smith+Nephew, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Finley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.